Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Nature genetics | Jul 28, 2011

http://www.ncbi.nlm.nih.gov/pubmed/21642991

Malignant pleural mesotheliomas (MPMs) often show CDKN2A and NF2 inactivation, but other highly recurrent mutations have not been described. To identify additional driver genes, we used an integrated genomic analysis of 53 MPM tumor samples to guide a focused sequencing effort that uncovered somatic inactivating mutations in BAP1 in 23% of MPMs. The BAP1 nuclear deubiquitinase is known to target histones (together with ASXL1 as a Polycomb repressor subunit) and the HCF1 transcriptional co-factor, and we show that BAP1 knockdown in MPM cell lines affects E2F and Polycomb target genes. These findings implicate transcriptional deregulation in the pathogenesis of MPM.

Pubmed ID: 21642991 RIS Download

Mesh terms: Adult | Aged | Apoptosis | Blotting, Western | Cell Nucleus | Cell Proliferation | Chromosomes, Human, Pair 3 | E2F Transcription Factors | Female | Humans | Immunoenzyme Techniques | Immunoprecipitation | Male | Mesothelioma | Middle Aged | Mutation | Pleural Neoplasms | Polycomb-Group Proteins | RNA, Messenger | Repressor Proteins | Reverse Transcriptase Polymerase Chain Reaction | Tumor Cells, Cultured | Tumor Suppressor Proteins | Ubiquitin Thiolesterase

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, Id: R01 CA169306

Comparative Toxicogenomics Database (Data, Disease Annotation)

Cellosaurus (Reagent, Cell Line)

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.